Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013


#168308

492pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. 

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Development by Companies 15
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Products under Development by Companies 27
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Products under Investigation by Universities/Institutes 34
Companies Involved in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development 35
Bristol-Myers Squibb Company 35
Johnson & Johnson 36
Boehringer Ingelheim GmbH 37
Amgen Inc. 38
AstraZeneca PLC 39
Eli Lilly and Company 40
Genentech, Inc. 41
Bavarian Nordic A/S 42
Isis Pharmaceuticals, Inc. 43
Merck & Co., Inc. 44
Oxford BioMedica plc 45
Takeda Pharmaceutical Company Limited 46
Plexxikon Inc. 47
Millennium Pharmaceuticals, Inc. 48
Novartis AG 49
Aphios Corporation 50
Astellas Pharma Inc. 51
BioMarin Pharmaceutical Inc. 52
GTx, Inc. 53
Nippon Shinyaku Co., Ltd. 54
Orion Corporation 55
SuperGen, Inc. 56
Teva Pharmaceutical Industries Limited 57
Progenics Pharmaceuticals, Inc. 58
Santaris Pharma A/S 59
Exelixis, Inc. 60
Aduro BioTech 61
Menarini Group 62
Bayer AG 63
Halozyme Therapeutics 64
Merck KGaA 65
Hollis-Eden Pharmaceuticals, Inc. 66
ValiRx Plc 67
Active Biotech AB 68
AEterna Zentaris Inc. 69
Northwest Biotherapeutics, Inc. 70
Cleveland BioLabs, Inc. 71
Oncothyreon Inc 72
Osta Biotechnologies Inc. 73
Peregrine Pharmaceuticals, Inc. 74
Medivation, Inc. 75
Regeneron Pharmaceuticals, Inc. 76
Oncogenex Pharmaceuticals, Inc. 77
Green Cross Corporation 78
Threshold Pharmaceuticals, Inc. 79
Synta Pharmaceuticals Corp. 80
e-Therapeutics plc 81
Hybrigenics S.A. 82
Cancer Research Technology Limited 83
Supratek Pharma Inc. 84
CellCentric Ltd. 85
Nerviano Medical Sciences S.r.l. 86
CureVac GmbH 87
GenSpera, Inc. 88
Tokai Pharmaceuticals, Inc. 89
TSD Japan, Inc. 90
BIND Biosciences, Inc. 91
NewLink Genetics Corporation 92
Bellicum Pharmaceuticals, Inc. 93
Kinex Pharmaceuticals, LLC 94
Adamis Pharmaceuticals Corporation 95
TRACON Pharmaceuticals, Inc. 96
Viamet Pharmaceuticals, Inc. 97
Aragon Pharmaceuticals, Inc. 98
GreenPeptide Co., Ltd. 99
Ausio Pharmaceuticals, LLC 100
Errant Gene Therapeutics, LLC 101
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 102
Assessment by Monotherapy Products 102
Assessment by Combination Products 103
Assessment by Route of Administration 104
Assessment by Molecule Type 106
Drug Profiles 109
AEZS-108 - Drug Profile 109
denosumab - Drug Profile 111
ipilimumab - Drug Profile 114
rilotumumab - Drug Profile 117
pasireotide - Drug Profile 119
patupilone - Drug Profile 122
sabarubicin - Drug Profile 124
DI-17-E-6 - Drug Profile 126
orteronel - Drug Profile 128
orteronel - Drug Profile 130
cixutumumab - Drug Profile 132
RG-7422 - Drug Profile 135
alisertib - Drug Profile 137
vandetanib - Drug Profile 140
PSMA ADC - Drug Profile 146
GTx-758 - Drug Profile 148
custirsen sodium - Drug Profile 149
ISIS-EIF4ERx - Drug Profile 152
OGX-427 - Drug Profile 154
olaparib - Drug Profile 156
ridaforolimus - Drug Profile 158
ASG-5-ME - Drug Profile 162
tasquinimod - Drug Profile 164
solitomab - Drug Profile 166
enzalutamide - Drug Profile 168
enzalutamide - Drug Profile 170
panobinostat - Drug Profile 172
AT-13387 - Drug Profile 177
HE-3235 - Drug Profile 180
AMPI-109 - Drug Profile 182
bafetinib - Drug Profile 183
Cyp17 Inhibitor Program - Drug Profile 185
TroVax - Drug Profile 186
dasatinib - Drug Profile 189
ramucirumab - Drug Profile 191
cabozantinib - Drug Profile 195
cabozantinib - Drug Profile 197
galeterone - Drug Profile 199
ganetespib - Drug Profile 200
rilimogene galvacirepvec - Drug Profile 204
mepacrine - Drug Profile 206
PX-866 - Drug Profile 208
DCVax Prostate - Drug Profile 210
radium Ra 223 dichloride - Drug Profile 211
bavituximab - Drug Profile 214
TSD-0014 - Drug Profile 219
AUS-131 - Drug Profile 221
Anti-PSMA Designer T Cells - Drug Profile 223
ETS-2123 - Drug Profile 224
CV-9103 - Drug Profile 225
BEZ-235 - Drug Profile 227
carlumab - Drug Profile 229
everolimus + [carboplatin] + [prednisone] - Drug Profile 231
bevacizumab + [docetaxel] + [prednisone] + [thalidomide] - Drug Profile 232
G-202 - Drug Profile 233
BMTP-11 - Drug Profile 235
VAL-201 - Drug Profile 236
ipilimumab + [sargramostim] - Drug Profile 237
DC-Tn-MUC1 Vaccine - Drug Profile 239
PLX-3397 - Drug Profile 240
docetaxel targeted nanoparticles - Drug Profile 242
atrasentan hydrochloride - Drug Profile 244
buparlisib - Drug Profile 245
custirsen sodium + [mitoxantrone hydrochloride] - Drug Profile 248
NLG-8189 - Drug Profile 250
TRC-105 - Drug Profile 252
vandetanib + [bicalutamide] - Drug Profile 255
afatinib - Drug Profile 257
HyperAcute-Prostate Cancer Vaccine - Drug Profile 259
GDC-0068 - Drug Profile 260
TH-302 + [gemcitabine hydrochloride] - Drug Profile 262
TH-302 + [doxorubicin] - Drug Profile 264
temsirolimus - Drug Profile 266
patupilone + [prednisone] - Drug Profile 267
Adenovirus/PSA Vaccine - Drug Profile 268
danusertib - Drug Profile 269
CreaVax-PC - Drug Profile 271
ARN-509 - Drug Profile 272
GVAX Prostate Cancer Vaccine - Drug Profile 274
TL-118 - Drug Profile 275
AZD-5363 - Drug Profile 277
inecalcitol - Drug Profile 279
JW-1521 - Drug Profile 281
OB-24 - Drug Profile 282
aflibercept - Drug Profile 284
EZN-4176 - Drug Profile 288
APH-0701 - Drug Profile 290
Lm-Prostate - Drug Profile 291
BPX-101 - Drug Profile 292
EZN-4176 + MDV-3100 - Drug Profile 294
LFA-102 - Drug Profile 295
KX-01 - Drug Profile 296
ODM-201 - Drug Profile 298
RG-7450 - Drug Profile 299
IRX-4204 - Drug Profile 300
SARD Program - Drug Profile 302
MG-1102 - Drug Profile 303
ITK-1 - Drug Profile 304
VT-464 - Drug Profile 306
TeloB-VAX - Drug Profile 307
VEL-015 - Drug Profile 308
AO-1530 - Drug Profile 310
Arkil - Drug Profile 311
CFG-920 - Drug Profile 312
PEGPH-20 - Drug Profile 313
CV-9104 - Drug Profile 314
AT-13387 + [abiraterone acetate] - Drug Profile 315
Dendritic Cell Vaccination + [docetaxel] - Drug Profile 316
chloroquine + [saracatinib] - Drug Profile 317
Deubiquitinase Program - Drug Profile 318
AGS-PSCA - Drug Profile 319
Growth Hormone - Releasing Hormone Antagonists - Drug Profile 320
cabazitaxel nanoformulation - Drug Profile 321
Compound-54 - Drug Profile 322
DCVAC/PCa - Drug Profile 323
IkappaB Kinase Alpha Inhibitors - Drug Profile 325
ATL-101 - Drug Profile 326
AKR1C3 Selective Inhibitors - Drug Profile 328
AbIMP Targeting ADAM15 - Drug Profile 329
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Drug Profile Updates 330
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Discontinued Products 463
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 466
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 472
Featured News & Press Releases 472

Appendix 483
Methodology 483
Coverage 483
Secondary Research 483
Primary Research 483
Expert Panel Validation 483
Contact Us 484
Disclaimer 484

Number of Products Under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2013 21
Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Investigation by Universities/Institutes, H1 2013 30
Comparative Analysis by Late Stage Development, H1 2013 31
Comparative Analysis by Mid Clinical Stage Development, H1 2013 32
Comparative Analysis by Early Clinical Stage Development, H1 2013 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Investigation by Universities/Institutes, H1 2013 42
Bristol-Myers Squibb Company, H1 2013 43
Johnson & Johnson, H1 2013 44
Boehringer Ingelheim GmbH, H1 2013 45
Amgen Inc., H1 2013 46
AstraZeneca PLC, H1 2013 47
Eli Lilly and Company, H1 2013 48
Genentech, Inc., H1 2013 49
Bavarian Nordic A/S, H1 2013 50
Isis Pharmaceuticals, Inc., H1 2013 51
Merck & Co., Inc., H1 2013 52
Oxford BioMedica plc, H1 2013 53
Takeda Pharmaceutical Company Limited, H1 2013 54
Plexxikon Inc., H1 2013 55
Millennium Pharmaceuticals, Inc., H1 2013 56
Novartis AG, H1 2013 57
Aphios Corporation, H1 2013 58
Astellas Pharma Inc., H1 2013 59
BioMarin Pharmaceutical Inc., H1 2013 60
GTx, Inc., H1 2013 61
Nippon Shinyaku Co., Ltd., H1 2013 62
Orion Corporation, H1 2013 63
SuperGen, Inc., H1 2013 64
Teva Pharmaceutical Industries Limited, H1 2013 65
Progenics Pharmaceuticals, Inc., H1 2013 66
Santaris Pharma A/S, H1 2013 67
Exelixis, Inc., H1 2013 68
Aduro BioTech, H1 2013 69
Menarini Group, H1 2013 70
Bayer AG, H1 2013 71
Halozyme Therapeutics, H1 2013 72
Merck KGaA, H1 2013 73
Hollis-Eden Pharmaceuticals, Inc., H1 2013 74
ValiRx Plc, H1 2013 75
Active Biotech AB, H1 2013 76
AEterna Zentaris Inc., H1 2013 77
Northwest Biotherapeutics, Inc., H1 2013 78
Cleveland BioLabs, Inc., H1 2013 79
Oncothyreon Inc, H1 2013 80
Osta Biotechnologies Inc., H1 2013 81
Medivation, Inc., H1 2013 83
Regeneron Pharmaceuticals, Inc., H1 2013 84
Oncogenex Pharmaceuticals, Inc., H1 2013 85
Green Cross Corporation, H1 2013 86
Threshold Pharmaceuticals, Inc., H1 2013 87
Synta Pharmaceuticals Corp., H1 2013 88
e-Therapeutics plc, H1 2013 89
Hybrigenics S.A., H1 2013 90
Cancer Research Technology Limited, H1 2013 91
Supratek Pharma Inc., H1 2013 92
CellCentric Ltd., H1 2013 93
Nerviano Medical Sciences S.r.l., H1 2013 94
CureVac GmbH, H1 2013 95
GenSpera, Inc., H1 2013 96
Tokai Pharmaceuticals, Inc., H1 2013 97
BIND Biosciences, Inc., H1 2013 99
NewLink Genetics Corporation, H1 2013 100
Kinex Pharmaceuticals, LLC, H1 2013 102
Adamis Pharmaceuticals Corporation, H1 2013 103
Aragon Pharmaceuticals, Inc., H1 2013 106
GreenPeptide Co., Ltd., H1 2013 107
Ausio Pharmaceuticals, LLC, H1 2013 108
Errant Gene Therapeutics, LLC, H1 2013 109
Assessment by Monotherapy Products, H1 2013 110
Assessment by Combination Products, H1 2013 111
Assessment by Stage and Route of Administration, H1 2013 113
Assessment by Stage and Molecule Type, H1 2013 116
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Drug Profile Updates 338
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Discontinued Products 471
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 474
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2013 21
Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 29
Late Stage Products, H1 2013 31
Mid Clinical Stage Products, H1 2013 32
Early Clinical Stage Products, H1 2013 33
Discovery and Pre-Clinical Stage Products, H1 2013 34
Assessment by Monotherapy Products, H1 2013 110
Assessment by Combination Products, H1 2013 111
Assessment by Route of Administration, H1 2013 112
Assessment by Stage and Route of Administration, H1 2013 113
Assessment by Molecule Type, H1 2013 114
Assessment by Stage and Molecule Type, H1 2013 115